Edwards SAPIEN XT transcatheter pulmonary valve implantation: 5-year follow-up in a French Registry.
adults
congential heart disease
heart disease intervention
percutaneous intervention
percutaneous valve therapy
pulmonary valve disease
stent design
structural
transcatheter valve implantation
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
revised:
08
06
2021
received:
30
09
2020
accepted:
18
06
2021
pubmed:
7
7
2021
medline:
15
12
2021
entrez:
6
7
2021
Statut:
ppublish
Résumé
This study sought to investigate patient intermediate-term outcomes after transcatheter pulmonary valve replacement (TPVR) with Edwards SAPIEN valve. The Edwards SAPIEN valve, initially designed for percutaneous aortic valve replacement, has been approved for TPVR in patients with dysfunctional right ventricular outflow tracts (RVOT), but only short-term follow-up has been reported. From 2011 to 2016, 62 patients undergoing successful TPVR using the SAPIEN XT valve were consecutively included into the study. Primary efficacy and safety endpoints were defined as freedom from valve-reintervention and freedom from infective endocarditis at last follow-up, respectively. The primary efficacy outcome was met for 87.1% patients after a mean follow-up of 4.6 ± 1.8 years, corresponding to a freedom of reintervention at 5 years of 89% (95% CI 74.8-95.6%). Reinterventions were exclusively due to recurrent obstruction, no significant valvular regurgitation was observed. One case of infective endocarditis was reported, corresponding to a rate of 0.35% per patient-year (95% CI 0.01-2.00%). At 5 years, freedom from infective endocarditis was 98.4% (95% CI 89.1-99.8%). Six patients died or were transplanted due to advanced cardiac failure, without relationship with TPVR. In univariate analysis, reintervention was associated with young age, a smaller tube-graft, a higher pulmonary valve gradient after the procedure and a ratio of largest implanted stent diameter to invasive balloon conduit diameter over 1.35. This study documents the mid-term safety and efficacy of the Edwards SAPIEN XT valve in patients with dysfunctional RVOT, and identifies a patient profile associated with an uncertain benefit-risk balance.
Sections du résumé
OBJECTIVES
This study sought to investigate patient intermediate-term outcomes after transcatheter pulmonary valve replacement (TPVR) with Edwards SAPIEN valve.
BACKGROUND
The Edwards SAPIEN valve, initially designed for percutaneous aortic valve replacement, has been approved for TPVR in patients with dysfunctional right ventricular outflow tracts (RVOT), but only short-term follow-up has been reported.
METHODS
From 2011 to 2016, 62 patients undergoing successful TPVR using the SAPIEN XT valve were consecutively included into the study. Primary efficacy and safety endpoints were defined as freedom from valve-reintervention and freedom from infective endocarditis at last follow-up, respectively.
RESULTS
The primary efficacy outcome was met for 87.1% patients after a mean follow-up of 4.6 ± 1.8 years, corresponding to a freedom of reintervention at 5 years of 89% (95% CI 74.8-95.6%). Reinterventions were exclusively due to recurrent obstruction, no significant valvular regurgitation was observed. One case of infective endocarditis was reported, corresponding to a rate of 0.35% per patient-year (95% CI 0.01-2.00%). At 5 years, freedom from infective endocarditis was 98.4% (95% CI 89.1-99.8%). Six patients died or were transplanted due to advanced cardiac failure, without relationship with TPVR. In univariate analysis, reintervention was associated with young age, a smaller tube-graft, a higher pulmonary valve gradient after the procedure and a ratio of largest implanted stent diameter to invasive balloon conduit diameter over 1.35.
CONCLUSIONS
This study documents the mid-term safety and efficacy of the Edwards SAPIEN XT valve in patients with dysfunctional RVOT, and identifies a patient profile associated with an uncertain benefit-risk balance.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
990-999Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Khanna AD, Hill KD, Pasquali SK, et al. Benchmark outcomes for pulmonary valve replacement using the Society of Thoracic Surgeons databases. Ann Thorac Surg. 2015;100:138-145.
Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356:1403-1405.
Cools B, Brown S, Budts W, et al. Up to 11 years of experience with the melody valved stent in the right ventricular outflow tract. EuroIntervention. 2018;14:e988-e994.
McElhinney DB, Benson LN, Eicken A, Kreutzer J, Padera RF, Zahn EM. Infective endocarditis after transcatheter pulmonary valve replacement using the melody valve: combined results of 3 prospective north American and European studies. Circ Cardiovasc Interv. 2013;6:292-300.
Jalal Z, Galmiche L, Lebeaux D, et al. Selective propensity of bovine jugular vein material to bacterial adhesions: an in-vitro study. Int J Cardiol. 2015;198:201-205.
Garay F, Webb J, Hijazi ZM. Percutaneous replacement of pulmonary valve using the Edwards-Cribier percutaneous heart valve: first report in a human patient. Catheter Cardiovasc Interv. 2006;67:659-662.
Plessis J, Hascoet S, Baruteau A, et al. Edwards SAPIEN Transcatheter pulmonary valve implantation: results from a French registry. JACC Cardiovasc Interv. 2018;11:1909-1916.
Kenny D, Rhodes JF, Fleming GA, et al. 3-year outcomes of the Edwards SAPIEN Transcatheter heart valve for conduit failure in the pulmonary position from the COMPASSION multicenter clinical trial. JACC Cardiovasc Interv. 2018;11:1920-1929.
Geva T. Repaired tetralogy of Fallot: the roles of cardiovascular magnetic resonance in evaluating pathophysiology and for pulmonary valve replacement decision support. J Cardiovasc Magn Reson. 2011;13:9.
Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound. J Am Soc Echocardiogr. 2009;22:975-1014.
Cheatham JP, Hellenbrand WE, Zahn EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation. 2015;131:1960-1970.
McElhinney DB, Sondergaard L, Armstrong AK, et al. Endocarditis after Transcatheter pulmonary valve replacement. J Am Coll Cardiol. 2018;72:2717-2728.
Georgiev S, Ewert P, Eicken A, et al. Munich comparative study: prospective long-term outcome of the Transcatheter melody valve versus surgical pulmonary bioprosthesis with up to 12 years of follow-up. Circ Cardiovasc Interv. 2020;13:e008963.
Bos D, De Wolf D, Cools B, et al. Infective endocarditis in patients after percutaneous pulmonary valve implantation with the stent-mounted bovine jugular vein valve: clinical experience and evaluation of the modified Duke criteria. Int J Cardiol. 2021;323:40-46.
Shahanavaz S, Qureshi AM, Levi DS, et al. Transcatheter pulmonary valve replacement with the melody valve in small diameter expandable right ventricular outflow tract conduits. JACC Cardiovasc Interv. 2018;11:554-564.
McElhinney DB, Cheatham JP, Jones TK, et al. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US melody valve trial. Circ Cardiovasc Interv. 2011;4:602-614.
Nombela-Franco L, Ribeiro HB, Urena M, et al. Incidence, predictive factors and haemodynamic consequences of acute stent recoil following transcatheter aortic valve implantation with a balloon-expandable valve. EuroIntervention. 2014;9:1398-1406.
Garg A, Parashar A, Agarwal S, et al. Comparison of acute elastic recoil between the SAPIEN-XT and SAPIEN valves in transfemoral-transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2015;85:490-496.
Martin C, Sun W. Transcatheter valve Underexpansion limits leaflet durability: implications for valve-in-valve procedures. Ann Biomed Eng. 2017;45:394-404.
Kreutzer J, Rome JJ. Open-cell design stents in congenital heart disease: a comparison of IntraStent vs Palmaz Stents. Catheter Cardiovasc Interv. 2002;56:400-409.
Rutledge JM, Mullins CE, Nihill MR, Grifka RG, Vincent JA. Initial experience with intratherapeutics Intrastent Doublestrut LD stents in patients with congenital heart defects. Catheter Cardiovasc Interv. 2002;56:541-548.
Carr M, Bergersen L, Marshall AC, et al. Bare metal stenting for obstructed small diameter homograft conduits in the right ventricular outflow tract. Catheter Cardiovasc Interv. 2013;81:E44-E52.
Cabalka AK, Hellenbrand WE, Eicken A, et al. Relationships among conduit type, pre-stenting, and outcomes in patients undergoing Transcatheter pulmonary valve replacement in the prospective north American and European melody valve trials. JACC Cardiovasc Interv. 2017;10:1746-1759.
Cocomello L, Meloni M, Rapetto F, et al. Long-term comparison between pulmonary homograft versus bioprosthesis for pulmonary valve replacement in tetralogy of Fallot. J Am Heart Assoc. 2019;8:e013654.
Egbe AC, Connolly HM, Miranda WR, Dearani JA, Schaff HV. Outcomes of bioprosthetic valves in the pulmonary position in adults with congenital heart disease. Ann Thorac Surg. 2019;108:1410-1415.
Soor GS, Leong SW, Butany J, Shapero JL, Williams WG. Pulmonary site bioprostheses: morphologic findings in 40 cases. Arch Pathol Lab Med. 2009;133:797-802.
Agarwal KC, Edwards WD, Feldt RH, Danielson GK, Puga FJ, McGoon DC. Clinicopathological correlates of obstructed right-sided porcine-valved extracardiac conduits. J Thorac Cardiovasc Surg. 1981;81:591-601.
Hascoet S, Dalla Pozza R, Bentham J, et al. Early outcomes of percutaneous pulmonary valve implantation using the Edwards SAPIEN 3 transcatheter heart valve system. EuroIntervention. 2019;14:1378-1385.
Breitbart P, Pache G, Minners J, et al. Influence of prosthesis-related factors on the occurrence of early leaflet thrombosis after transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2020;21:1082-1089.
Shahanavaz S, Zahn EM, Levi DS, et al. Transcatheter pulmonary valve replacement with the Sapien prosthesis. J Am Coll Cardiol. 2020;76:2847-2858.
Silvilairat S, Cabalka AK, Cetta F, Hagler DJ, O'Leary PW. Echocardiographic assessment of isolated pulmonary valve stenosis: which outpatient Doppler gradient has the most clinical validity? J Am Soc Echocardiogr. 2005;18:1137-1142.